Skip to main content

A phase 3 combination study investigating the safety and efficacy of intravenous injection of IMP or sham administered in subjects with subfoveal neovascular AMD. The sponsor was a small US biotech developing innovative treatments for patients with orphan or inherited retinal diseases with significant unmet medical needs.